

## AGENDA



**POETIC Winter Meeting**  
**February 7 and 8<sup>th</sup>, 2018**  
**The Alford Inn**  
**300 East New England Avenue**  
**Winter Park, FL**

Time	Session
<b>Tuesday, February 6<sup>th</sup></b> <b>[The Alford Inn Boardroom]</b>	
6:00 PM EST	<b>Board of Directors Meeting (Closed Meeting)</b>
7:00 PM	<b>Dinner</b> <b>Board of Directors</b> <b>[The Alford Inn, Winter Park, FL]</b>
<b>Wednesday, February 7<sup>th</sup></b> <b>[New England Room]</b>	
8:00 – 8:30 AM	<b>Registration/Breakfast</b>
8:30 – 8:45 AM	<b>Greetings/Introductions</b> <i>Amy Smith, MD Arnold Palmer Hospital for Children</i> <i>Cary D'ortona, Chief Operating Officer, Arnold Palmer Hospital for Children</i>  <b>Welcome Address</b> <i>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i> <i>Co-Founder and Director, POETIC</i>
8:45 – 10:15 AM	<b>Targeted Delivery of PV-10 in Pediatric Malignancies</b> <b><i>Mechanistic Studies and Preclinical Development of PV-10</i></b> <i>Eric Wachter, PhD, Chief Technology Officer and Director, Provectus Biopharmaceuticals, Inc.</i> <i>Shari Pilon-Thomas, PhD, Associate Member, Department of Immunology, Moffitt Cancer Center and Research Institute</i> <i>Stephanie Hansen, Director of Clinical Operations, Provectus Biopharmaceuticals, Inc.</i>  <b><i>Pediatric Preclinical Studies of PV-10</i></b> <i>Aru Narendran, MD, PhD/Olga Kovalchuk, MD, PhD</i> <i>Srikanth Ambati, MD</i>  <b><i>Clinical Trial of PV-10 in Pediatric Oncology</i></b> <i>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i> <i>Eric Wachter, PhD</i>
10:15 – 10:30 AM	<b>Break</b>

<b>10:30 – 11:30 AM</b>	<b>Preclinical Development of miR loaded Exosomal Vesicles</b> <i>Stephen Gould, PhD, Professor Biologic Chemistry, Johns Hopkins University</i> <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i>
<b>11:30 AM – 12:00 PM</b>	<b>Molecular and Immunologic Profiling in Relapsed/Refractory Pediatric Tumors – A POETIC Multicenter Biology study</b> <i>Srikanth Ambati, MD, Memorial Sloan Kettering Cancer Center</i> <i>Norman Lacayo, MD, Lucile Packard</i>
<b>Lunch [Served on Site]</b>	
<b>AFTERNOON SESSION</b>	
<b>1:00 – 5:30 PM</b>	<b>POETIC Translational Genomics Program</b>
<b>1:00 – 1:45 PM</b>	<b><i>Comprehensive overview of IMPACT and cfDNA Analysis in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>Michael Berger, PhD, Memorial Sloan Kettering Cancer Center</i>
<b>1:45 – 2:15 PM</b>	<b><i>Exosomal Analysis in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i>
<b>2:15 – 2:45 PM</b>	<b><i>Proteomic Analysis in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center</i>
<b>2:45 – 3:00 PM</b>	<b>Break</b>
<b>3:00 – 3:30 PM</b>	<b><i>Epigenomics (DNA) in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>Bodour Salhia, PhD, USC</i>
<b>3:30 - 4:00 PM</b>	<b><i>Epigenomics (RNA) in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>Olga Kovalchuk, MD, PhD, University of Lethbridge</i>
<b>4:00 – 4:30 PM</b>	<b><i>Immune Profiling in Pediatric Patients with Recurrent/Relapsed Malignancies</i></b> <i>Srikanth Ambati, MD, Memorial Sloan Kettering Cancer Center</i>
<b>4:30 – 5:00 PM</b>	<b><i>cBioPortal</i></b> <i>Angelica Ochoa, PhD, Memorial Sloan Kettering Cancer Center</i>
<b>5:00 – 5:30 PM</b>	<b><i>International Expansion of POETIC Translational Genomics Program</i></b> <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i> <i>Bodour Salhia, PhD, University of Southern California</i>
<b>5:30 PM</b>	<b>Meeting Adjourn</b>
<b>Dinner</b> <b>Luma on Park</b> <b>290 South Park Avenue</b> <b>Winter Park, FL</b>	

**Thursday, February 8<sup>th</sup>**  
**[The Alfond Inn Boardroom]**

<b>8:00 – 8:45 AM</b>	<b>PI Meeting (Closed Meeting in Park 4 Room)</b> <i>Tanya Trippett, MD, Co-Founder and Director POETIC</i> <i>Cynthia Herzog, MD, MD Anderson Cancer Center</i> <i>Lisa McGregor, MD, Pennsylvania State Medical Center</i> <i>Joseph DeStefano, Research Program Director, POETIC, MSKCC</i> <i>Obiageli Nwankwo, Research Project Manager, POETIC, MSKCC</i> <i>Amina Ahmed, Research Project Manager, POETIC, MSKCC</i>
<b>8:45 – 9:00 AM</b>	<b>Registration/Breakfast</b>
<b>9:00 – 10:00 AM</b>	<b>Next Generation Sequencing for Infectious Disease Diagnostics</b>
<b>9:00 – 9:30 AM</b>	<i>Catherine Aftandilian, MD, Lucile Packard Children’s Hospital</i>
<b>9:30 - 10:00 AM</b>	<i>David Hong, MD, Medical Director, Karius Dx</i>
<b>10:00 – 10:15 AM</b>	<b>Break</b>
<b>10:45 – 11:15 AM</b>	<b>Preclinical Development of Taurolidine NanoPro™</b> <i>Tony Pfaffle, MD, Chief Scientific Officer, Cormedix, Inc.</i> <i>Presentation by Aru Narendran, MD, PhD</i> <i>Presentation by Srikanth Ambati, MD</i>
<b>11:15 – 12:15 PM</b>	<b>NeuroOncology Initiatives</b> <i>Aru Narendran, MD, PhD Alberta Children’s Hospital</i> <i>Amy Smith, MD, Arnold Palmer Hospital</i>
<b>Lunch</b>	
<b>1:00 – 1:30 PM</b>	<b>Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide</b> <i>PI, Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD</i>
<b>1:30 – 2:00 PM</b>	<b>Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session)</b> <i>Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i> <i>Michael Kellick, PharmD, Memorial Sloan Kettering Cancer Center</i>
<b>2:00 – 2:15 PM</b>	<b>Break</b>
<b>2:15 – 2:45 PM</b>	<b>Concept of Selinexor/Carfilzomib</b> <i>Norman Lacayo, MD, Lucile Packard Children’s Hospital</i> <i>Liora Schultz, MD, Lucile Packard Children’s Hospital</i>
<b>2:45 – 3:00 PM</b>	<b>Outtake</b>
<b>3:00 PM</b>	<b>Adjourn</b>